We are live on ! Find out more
VTVT icon

vTv Therapeutics
VTVT

17 hedge funds and large institutions have $7.57M invested in vTv Therapeutics in 2024 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

3% more capital invested

Capital invested by funds: $7.34M → $7.57M (+$233K)

1.19% less ownership

Funds ownership: 22.32% → 21.13% (-1.2%)

15% less funds holding

Funds holding: 20 → 17 (-3)

67% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 3

Holders
17
Holders Change
-3
Holders Change %
-15%
% of All Funds
0.22%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
5
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$98.3K
2
JP Morgan Chase
JP Morgan Chase
New York
+$26.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$19.6K
4
Morgan Stanley
Morgan Stanley
New York
+$4.53K
5
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$1.29K

Top Sellers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
-$3.65K
2
SFCL
Strengthening Families & Communities LLC
Massachusetts
-$2.35K
3
PS
Planned Solutions
California
-$339
4
Osaic Holdings
Osaic Holdings
Arizona
-$118
Name Holding Trade Value Shares
Change 		Change in
Stake
SB
1
Samsara BioCapital
California
$2.86M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$2.43M – – –
BBA
3
Baker Bros. Advisors
New York
$1.34M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$566K – – –
Geode Capital Management
5
Geode Capital Management
Massachusetts
$158K +$19.6K +1,327 +13%
UBS Group
6
UBS Group
Switzerland
$104K +$98.3K +6,646 +767%
BlackRock
7
BlackRock
New York
$65.9K +$340 +23 +0.5%
JP Morgan Chase
8
JP Morgan Chase
New York
$24.6K +$26.7K +1,803 New
Morgan Stanley
9
Morgan Stanley
New York
$15.8K +$4.53K +306 +36%
Royal Bank of Canada
10
Royal Bank of Canada
Ontario, Canada
$5K +$1.29K +87 +29%
Osaic Holdings
11
Osaic Holdings
Arizona
$2.35K -$118 -8 -4%
AWM
12
Activest Wealth Management
Florida
$690 – – –
PA
13
Parallel Advisors
California
$525 – – –
CPG
14
Cornerstone Planning Group
New Jersey
$268 – – –
SS
15
Sunbelt Securities
Texas
$210 – – –
BNP Paribas Financial Markets
16
BNP Paribas Financial Markets
France
$124 – – –
Bank of America
17
Bank of America
North Carolina
$110 – – –
TRCT
18
Tower Research Capital (TRC)
New York
– -$3.65K -269 Closed
SFCL
19
Strengthening Families & Communities LLC
Massachusetts
– -$2.35K -173 Closed
PS
20
Planned Solutions
California
– -$339 -25 Closed

VTVT Hedge Fund Activity: Q4 2024 in Review

17 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in vTv Therapeutics (VTVT) for Q4 2024, worth a combined $7.57M — up 3.2% from $7.34M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of VTVT and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 5 added.

The largest buyer was UBS Group, adding an estimated $98.3K. The largest seller was Tower Research Capital (TRC), exiting entirely with an estimated $3.65K sold.

  • 17 institutional investors held vTv Therapeutics (VTVT) as of Q4 2024, down from 20 in Q3 2024.
  • Funds reported $7.57M of vTv Therapeutics stock for Q4 2024, up 3.2% quarter-over-quarter.
  • 1 fund opened new vTv Therapeutics positions in Q4 2024 and 3 closed out, a net change of -2 holders.
  • The largest vTv Therapeutics buyer in Q4 2024 was UBS Group, an estimated $98.3K added.
  • The largest vTv Therapeutics seller in Q4 2024 was Tower Research Capital (TRC), an estimated $3.65K sold.

Based on aggregated 13F filings for Q4 2024.